Manali Kamdar, MD, MBBS, discusses the efficacy and tolerability of a phase 1 clinical trial testing a novel anti-CD19 chimeric antigen receptor T-cell product in adults with relapsed/refractory B-cell lymphoma.
Videos
Lori J. Wirth, MD, discusses a new assay with the ability to perform DNA and RNA sequencing to better detect gene fusions.
Alicia Morgans, MD, MPH, presents the case of a 67-year-old man with metastatic castration-resistant prostate cancer.
Expert panelists consider later-line treatment options for a patient with recurrent hepatocellular carcinoma.
Comprehensive insight on several clinical trials analyzing frontline combination therapies for patients with unresectable hepatocellular carcinoma.
Experts share their thoughts on sequencing hormonal agents and patient selection for clinical trials.
In the setting of unresectable hepatocellular carcinoma, experts consider the role of frontline atezolizumab + bevacizumab given data from IMbrave150.
Samuel J. Klempner, MD, discusses the preliminary results of a study of the investigational agent DKN-01 for patients with gastroesophageal adenocarcinoma.
Shana Wingo, MD, discusses the key goals of the partnership between community oncology practices and American Oncology Network.
Erika P. Hamilton, MD, discusses the evolution of fam-trastuzumab deruxtecan-nxki through its examination in various trials.
Lori J. Wirth, MD, explains the role of NTRK inhibitor in TRK fusion-positive thyroid cancer treatment.
Closing out the program, Robert Zeiser, MD, shares what he is looking forward to in the field of graft-vs-host-disease.
Adverse events related to chronic graft-vs-host-disease therapies and strategies to manage these adverse effects are considered.
Robert Zeiser, MD, touches on additional therapeutic options for steroid-refractory chronic graft-vs-host-disease, such as extracorporeal photopheresis, mycophenolate, everolimus, and more.
Therapies for steroid-refractory chronic graft-vs-host disease, ibrutinib, ruxolitinib, and belumosudil, are explored in a comprehensive analysis.
A GVHD expert comments on the frontline therapy available for the condition.
Selection of prophylaxis regimen is reviewed followed by a discussion of the typical patient presentation of GVHD.
Dr Zeiser outlines the differences between acute and chronic GVHD and also reviews factors that put transplant patients at greater risk of GVHD.
Alexander Drilon, MD, discusses the differences in how TRK fusions manifest in older patients vs younger patients.
A review of recent data from the TheraP trial.
Tanya Dorff, MD, explains safety and efficacy data from the CARD trial.
Michael J. Morris, MD, discusses the results of the VISION trial of 177-lutetium-PSMA-61 in patients with metastatic castration-resistant prostate cancer.
Hagop M. Kantarjian, MD, discusses the impact of prominent treatments in acute lymphoblastic leukemia.
Before closing out their discussion on metastatic CSPC, expert oncologists consider how best to educate patients and address the remaining unmet needs in this setting.
A key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.
Emphasizing the variety of options available in the second-line setting, Chau T. Dang, MD, remarks on the case of a patient with HER2+ mBC and highlights key factors affecting therapeutic decision-making.
After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.
Bruce Feinberg, DO, explains how chimeric antigen receptor T cells were introduced in hematologic malignancies.
Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.
Mazyar Shadman, MD, MPH, discusses the results of his research on MB-106 as treatment for patients with relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.